Treatment
Paclitaxel clinical trials
We’re tracking 669 recruiting studies that include Paclitaxel, each written for real people, not researchers, below.
Recruiting studies
- NCT04894643Recruiting
Pre-surgery proton radiation plus chemo for borderline pancreatic cancer
This trial tests whether giving proton radiation and chemotherapy before surgery can shrink or control “borderline resectable” pancreatic cancer so it can be removed more effectively. It may help by improving treatment response while planning for surgery afterward.
Wiener Neustadt, Lower AustriaAges 18 years+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT04859465RecruitingPhase 2
Paclitaxel plus doxorubicin for advanced, unresectable angiosarcoma
This Phase 2 trial tests a chemotherapy combination (paclitaxel and liposomal doxorubicin) for people with advanced angiosarcoma that cannot be removed by surgery. It is meant for cases where standard treatment either did not work or was too hard to tolerate, and it aims to shrink tumors and control the disease.
Guangzhou, GuangdongAges 18–70 - NCT04821843RecruitingPhase 3
Study before-surgery treatments for esophageal cancer
This Phase 3 trial compares different “treatments before surgery” for people with esophageal (or esophagus-to-stomach) cancer. It aims to see which approach works better to control the cancer and improve outcomes after surgery.
BeijingAges 18 years+ - NCT04821778RecruitingPhase 3
Testing chemoradiotherapy for esophageal and stomach junction cancer
This Phase 3 study tests a cancer treatment plan that combines chemotherapy and radiation for people with esophageal or esophagus-stomach junction cancer. It aims to see whether this approach works better than standard care for cancers at stages I to IVA.
Anyang, HenanAges 18 years+ - NCT04771871RecruitingPhase 2
Study tiny RNA changes in triple-negative breast cancer
This trial studies patterns of microRNA (tiny gene-regulating molecules) in women with triple-negative breast cancer. By comparing these microRNA profiles, the study hopes to better understand the disease and potentially guide future treatment choices.
Ile-Ife, OshunAges 18–70 - NCT04722523RecruitingPhase 1
Cemiplimab plus chemo and other immune treatment for head and neck cancer
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
Basking Ridge, New JerseyAges 18 years+ - NCT04752826RecruitingPhase 1/Phase 2
A new drug combo for advanced cancers
This trial tests a new experimental drug, BI-1808, alone or with an approved cancer drug called pembrolizumab (Keytruda). It's for people with advanced cancers that have stopped responding to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT04615013RecruitingPhase 1
NBTXR3 with chemoradiation for esophageal cancer treatment
This early-phase study tests adding NBTXR3 (a special treatment given into the tumor) to standard chemotherapy and radiation for esophageal cancer. The goal is to see if it can improve cancer control and to learn about safety and dosing.
Houston, TexasAges 18 years+ - NCT04516447RecruitingPhase 1
Testing a new drug for advanced ovarian cancer
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
Aurora, ColoradoAges 18 years+ - NCT04585490RecruitingPhase 3
Testing a personalized add-on treatment after stage III lung cancer
This phase 3 trial tests whether tailoring the next (add-on) treatments can improve outcomes after standard chemoradiation and immunotherapy for stage III, unresectable (not operable) non-small cell lung cancer. It specifically looks at giving durvalumab plus an additional drug (tremelimumab) and possibly other consolidation chemotherapy based on a personalized plan.
Stanford, CaliforniaAges 18 years+ - NCT04400695RecruitingPhase 3
Targeted drug for breast cancer with low HER2 levels
This trial tests a new drug that targets breast cancer cells with low levels of the HER2 protein. It may offer a new treatment option for patients whose cancer has spread and not responded well to previous therapies.
Beijing, Beijing MunicipalityAges 18–70 - NCT04267848RecruitingPhase 3
Testing immunotherapy with chemo after lung cancer surgery
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
Anchorage, AlaskaAges 18 years+ - NCT04342910RecruitingPhase 3
Test camrelizumab plus apatinib for advanced stomach cancer
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
BeijingAges 18 years+ - NCT04329065RecruitingPhase 2
Vaccine with targeted breast cancer drugs before surgery
This Phase 2 trial tests whether adding a cancer vaccine (with GM-CSF) to standard HER2-targeted chemotherapy before surgery improves treatment outcomes for HER2-positive breast cancer. If you join, you’ll receive planned medicine before surgery to treat the tumor, then continue with the study schedule.
Seattle, WashingtonAges 18 years+ - NCT04332367RecruitingPhase 2
New chemo plus ramucirumab for lung cancer after maintenance
This Phase 2 trial studies a combination of chemotherapy (carboplatin and a “taxane”) plus ramucirumab for people with advanced lung cancer that came back or progressed after prior maintenance treatment. It may help by attacking cancer growth after earlier therapy no longer worked.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04297605RecruitingPhase 1
Pembrolizumab plus chemotherapy for advanced lung cancer
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
Rochester, New YorkAges 18 years+ - NCT04165070RecruitingPhase 1/Phase 2
Stage IV lung cancer trial using pembrolizumab with or without chemotherapy
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
Gilbert, ArizonaAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT03424005RecruitingPhase 1/Phase 2
Testing new drug combinations for advanced breast cancer
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Duarte, CaliforniaAges 18 years+ - NCT02610439Recruiting
Genetic testing to find causes of paclitaxel nerve damage
This study uses genetic tests on blood DNA to look for differences that may explain why some people develop nerve pain (peripheral neuropathy) from paclitaxel used for breast cancer. It compares people who got significant neuropathy during treatment with people who did not get neuropathy after completing paclitaxel.
Boston, MassachusettsAges Any age
Common questions
- Are there clinical trials studying Paclitaxel?
- Yes. Clin2 currently lists 669 recruiting studies that include Paclitaxel, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Paclitaxel trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Paclitaxel an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Paclitaxel or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.